Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
=== Others === Rare cases of liver toxicity have been observed, possibly due to the formation of reactive metabolites. Elevated prolactin concentrations have been observed in people taking trazodone. They appear to be increased by around 1.5- to 2-fold. Studies on trazodone and cognitive function are mixed, with some finding improvement and others finding no change. Trazodone does not seem to worsen periodic limb movements during sleep. Trazodone is associated with an increased risk of falls in older adults. It has also been associated with increased risk of hip fractures in older adults.
US defense secretary Pete Hegseth announced Operation Southern Spear would begin later in November, with a fleet using robotics and autonomous systems to target Latin American drug trafficking. Experts, the Trump administration, and Venezuelan opposition sources stated that a likely goal of the operation is to force the departure of top figures in the Nicolás Maduro government. By the end of November 2025, the Cartel of the Suns—which the US alleges is headed by Maduro, and Maduro denies—was designated as a Foreign Terrorist Organization, allowing for expanded US options, and in late December, the US made its first strike on a target within Venezuela. The buildup culminated in a series of strikes on Venezuelan military and civilian air infrastructure, and the capture of Maduro by the US armed forces in a predawn raid on 3 January 2026. Maduro contends the US is after Venezuela's oil; Trump does not dispute this.
In 2022, the COSMIC confidence score was added to the CSI:FingerID structure identification workflow in SIRIUS 4, allowing users to determine the trustworthiness of the identification. In 2024, the de novo generation of candidate structures through MSNovelist was introduced with SIRIUS 6.
== Pharmacology == Omeprazole irreversibly blocks the enzyme system on parietal cells that is needed for the secretion of gastric acid. It is a specific H+/K+ATPase inhibitor. This is the enzyme needed for the final step in the secretion of gastric acid.
Soldiers and ninja also used "pills", small ball-shaped medicinal rations consumed in emergencies or long missions, of which there were three types: hyorogan ("ration pills"), made with various flours, sugary substances, and spices to provide quick energy; kikatsugan ("hunger pills"), made with starchy ingredients to provide endurance; and suikitsugan ("thirst pills"), made from umeboshi, bakumondoto, and sugar to encourage saliva production. Tang dynasty soldiers ate primarily millet porridge, but before a deployment, they would have a large and elaborate banquet, with another large meal before a battle. Song dynasty soldiers were issued money for food and bought meat, vegetables, pickles, and salt locally. Grain supply issues meant they relied less on grain rations than in prior generations. During the Ming dynasty, sesame seed cakes, which could last long periods of time, became standard military food and wheat began to take an important position in rations. The imperial government spent significant amounts of money on the military, investing more into supplying the army with food than previous dynasties. A system of military farmlands, comprising 10% of cultivated land, was organized to supply the army. The state assigned 10% to 20% of military households in each region with running military farms and provided them with seeds and tools to grow grain. Other farmers delivered grain to supplement bad growing seasons. In 1392, this system was designed to feed 1.2 million soldiers.
Sources: en.wikipedia.org
=== International response === The international community tends to react adversely to coups by reducing aid and imposing sanctions. A 2015 study finds that "coups against democracies, coups after the Cold War, and coups in states heavily integrated into the international community are all more likely to elicit global reaction." Another 2015 study shows that coups are the strongest predictor for the imposition of democratic sanctions. A third 2015 study finds that Western states react most strongly against coups of possible democratic and human rights abuses. A 2016 study shows that the international donor community in the post-Cold War period penalizes coups by reducing foreign aid. The US has been inconsistent in applying aid sanctions against coups both during the Cold War and post-Cold War periods, a likely consequence of its geopolitical interests. Organizations such as the African Union (AU) and the Organization of American States (OAS) have adopted anti-coup frameworks. Through the threat of sanctions, the organizations actively try to curb coups. A 2016 study finds that the AU has played a meaningful role in reducing African coups. A 2017 study found that negative international responses, especially from powerful actors, have a significant effect in shortening the duration of regimes created in coups. According to a 2020 study, coups increase the cost of borrowing and increase the likelihood of sovereign default.
The surface of the rough endoplasmic reticulum (often abbreviated RER or rough ER; also called granular endoplasmic reticulum) is studded with protein-manufacturing ribosomes giving it a "rough" appearance (hence its name). The binding site of the ribosome on the rough endoplasmic reticulum is the translocon. However, the ribosomes are not a stable part of this organelle's structure as they are constantly being bound and released from the membrane. A ribosome only binds to the RER once a specific protein-nucleic acid complex forms in the cytosol. This special complex forms when a free ribosome begins translating the mRNA of a protein destined for the secretory pathway. The first 5–30 amino acids polymerized encode a signal peptide, a molecular message that is recognized and bound by a signal recognition particle (SRP). Translation pauses and the ribosome complex binds to the RER translocon where translation continues with the nascent (new) protein forming into the RER lumen and/or membrane. The protein is processed in the ER lumen by an enzyme (a signal peptidase), which removes the signal peptide. Ribosomes at this point may be released back into the cytosol; however, non-translating ribosomes are also known to stay associated with translocons. The membrane of the rough endoplasmic reticulum is in the form of large double-membrane sheets that are located near, and continuous with, the outer layer of the nuclear envelope.
Carnitine is an essential cofactor for mitochondrial transport of long‑chain fatty acids (a major lipid class) into the matrix for β‑oxidation. gamma-aminobutyric acid is a neurotransmitter. 5-HTP (5-hydroxytryptophan) is used for experimental treatment of depression. L-DOPA (L-dihydroxyphenylalanine) for Parkinson's treatment, Eflornithine inhibits ornithine decarboxylase and used in the treatment of sleeping sickness. Canavanine, an analogue of arginine found in many legumes is an antifeedant, protecting the plant from predators. Mimosine found in some legumes, is another possible antifeedant. This compound is an analogue of tyrosine and can poison animals that graze on these plants. However, not all of the functions of other abundant nonstandard amino acids are known.
Antidotes are agents that can neutralise the effects of a poison or toxin. Antidotes counteract the effects of toxins in many ways, such as by blocking the absorption of the toxin, binding and neutralising the poison, opposing the toxin's end-organ function, or blocking the toxin's conversion to more hazardous metabolites. In addition to lowering the amount of free or active poison present, antidote delivery may also lessen the toxin's effects on organs through competitive inhibition, receptor blockage, or direct antagonistic interaction. The therapeutic index or ratio (TD50/ED50), which is the ratio of the toxic dosage (TD) or fatal dose (LD) to the effective dose (ED), determines the level of safety associated with a substance.
Although phosphorus (15P) has 22 known isotopes from 26P to 47P, only 31P is stable; Phosphorus is thus considered a monoisotopic element. 31P is also the only naturally occurring isotopes of phosphorus, so phosphorus is considered a mononuclidic element as well. The longest-lived radioactive isotopes are 33P with a half-life of 25.35 days and 32P with a half-life of 14.269 days. All others have half-lives of under 2.5 minutes, most under a second.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.